NATHALIE ORR: Open Payments
NPI 1417316357 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$975 in 45 payments from 15 companies in 2025. Trend: 2023 $842 · 2024 $1,041 · 2025 $975
Food & beverage: $975
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $171 |
| Janssen Biotech, Inc. | 7 | $151 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $133 |
| Madrigal Pharmaceuticals | 4 | $116 |
| ABBVIE INC. | 5 | $87 |
| Regeneron Healthcare Solutions, Inc. | 4 | $76 |
| Lilly USA, LLC | 2 | $44 |
| Ipsen Biopharmaceuticals, Inc | 1 | $34 |
| Celltrion USA Inc. | 2 | $34 |
| GENZYME CORPORATION | 1 | $26 |
Products named: TREMFYA, XIFAXAN, REZDIFFRA, DUPIXENT, ENTYVIO, RINVOQ, GATTEX, OMVOH.
Industry payments across MD — which companies pay providers there.
